Ivosidenib in IDH1-mutant, chemotherapy-refractory...

  • Main
  • 2020 / 5
  • Ivosidenib in IDH1-mutant, chemotherapy-refractory...
The Lancet Oncology 2020 / 5

Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study

Abou-Alfa, Ghassan K, Macarulla, Teresa, Javle, Milind M, Kelley, Robin K, Lubner, Sam J, Adeva, Jorge, Cleary, James M, Catenacci, Daniel V, Borad, Mitesh J, Bridgewater, John, Harris, William P, Mur
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Journal:
The Lancet Oncology
DOI:
10.1016/S1470-2045(20)30157-1
Date:
May, 2020
File:
PDF, 1.45 MB
2020
Conversion to is in progress
Conversion to is failed